Increased dupilumab utilization coincided with decreased ESS in patients with CRSwNP between 2019 and 2021. One potential confounder was the concurrent COVID-19 pandemic, which may have negatively impacted surgery utilization rates.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/alr.23325 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of smoking on biological treatment response in patients from the German Severe Asthma (GAN) Registry.
J Allergy Clin Immunol Pract
January 2025
Clinic of Internal Medicine II - Department of Pneumology, Medical University of Vienna - Vienna (Austria). Electronic address:
Background: Clinical studies of biologics in severe asthma exclude smokers or ex-smokers (ExS) with over 10 pack-years (py). Thus, the effectiveness of this therapy in ex-smokers with severe asthma is not well understood.
Objectives: To assess the impact of smoking on clinical efficiency of biologics in patients with severe asthma from the German Asthma Net (GAN), a comprehensive international registry.
The impact of dupilumab on sleep disruptions in patients with prurigo nodularis: A systematic review and meta analysis.
J Eur Acad Dermatol Venereol
December 2024
Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.
Introduction: Emerging evidences have underscored the positive impact of biologics on asthmatic patients. However, there is a pressing need to verify their therapeutic efficacy in children and adolescents with asthma. To address this, we conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of biologics in the asthma management of this demographic.
View Article and Find Full Text PDFSingle-centre retrospective review of dupilumab-induced ocular surface disease in an Australian adult cohort with moderate-to-severe atopic dermatitis.
Australas J Dermatol
December 2024
Dermatology Department, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Treatment and management outcomes or patients with atopic dermatitis has significantly improved with the inclusion of dupilumab into the pharmaceutical benefits scheme, as a safe and effective treatment. Ocular surface disease remains one of the most frequent adverse events seen with dupilumab, and impacts quality of life and can interrupt treatment. This retrospective review aims to further characterise the experience and risk factors of dupilumab-induced ocular surface disease to inform management and support long-term use for patients, improving overall treatment outcomes.
View Article and Find Full Text PDFDupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of The Literature.
Dermatol Pract Concept
October 2024
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Introduction: Dupilumab, a monoclonal antibody targeting IL-4 receptor subunit alpha, treats atopic dermatitis (AD) and may impact alopecia areata (AA). AA involves Th1-driven immune activity, and recent studies suggest a role for Th2 pathways. Dupilumab's effects on AA are mixed, with reports of both improvement and worsening.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!